<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013111</article-id><article-id pub-id-type="pmc">PMC11860868</article-id><article-id pub-id-type="doi">10.3389/fped.2025.1505233</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Case Report</subject></subj-group></subj-group></article-categories><title-group><article-title>Increase in methemoglobin fraction due to the use of glyceryl trinitrate patches in preterm infants: a case report and literature review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Calandrino</surname><given-names>Andrea</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2756809/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Vinci</surname><given-names>Francesco</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1334322/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Battaglini</surname><given-names>Marcella</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2964363/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Caruggi</surname><given-names>Samuele</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2964327/overview"/><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Andreato</surname><given-names>Chiara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2964324/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Montobbio</surname><given-names>Carolina</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2964338/overview"/><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Vannati</surname><given-names>Marianna</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2964339/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Minghetti</surname><given-names>Diego</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2964321/overview"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Brigati</surname><given-names>Giorgia</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1190678/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Ramenghi</surname><given-names>Luca Antonio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/613260/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Mother and Child Health, School of Medical and Pharmaceuticals, University of Genoa</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Neonatal Intensive Care Unit, Department of Maternal and Neonatal Health, IRCCS Istituto Giannina Gaslini</institution>, <addr-line>Genoa</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Qiuping Li, Bayi Children's Hospital, China</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Serafina Perrone, University of Parma, Italy</p><p>Deepika Wagh, Child and Adolescent Health Service, Australia</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Francesco Vinci <email>francescovinci@gaslini.org</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>1505233</elocation-id><history><date date-type="received"><day>02</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Calandrino, Vinci, Battaglini, Caruggi, Andreato, Montobbio, Vannati, Minghetti, Brigati and Ramenghi.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Calandrino, Vinci, Battaglini, Caruggi, Andreato, Montobbio, Vannati, Minghetti, Brigati and Ramenghi</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>Oxidized heme iron forms methemoglobin (MeHb), impairing the oxygen-binding capability of hemoglobin molecules. Nitric oxide (NO) obtained from glyceryl trinitrate (GTN) patches can cause MeHb formation during limb ischemia topical treatment. This case reports a preterm infant treated with multiple GTN patches who developed elevated MeHb levels, a potential therapy complication.</p></sec><sec><title>Case presentation</title><p>A preterm female newborn (25&#x02009;+&#x02009;4 weeks, 560&#x02005;g) was delivered by cesarean due to maternal HELLP syndrome and intubated for respiratory distress. After developing ischemia in her right hand and foot, GTN patches were applied, but therapy caused a peak in methemoglobin (MeHb) levels, prompting patch removal. MeHb levels normalized after 18&#x02005;h, and after adjusting therapy, ischemia resolved successfully.</p></sec><sec><title>Discussion</title><p>We report the case of a premature IUGR infant who developed elevated methaemoglobin (MeHb) levels during topical GTN therapy for catheter-related extremity ischemia. While GTN is effective for neonatal ischemia, its dosing, and safety lack consistent guidelines. Elevated MeHb levels, noted in similar cases here reviewed, can impair oxygen exchange, especially in vulnerable preterm infants with immature skin and reduced enzyme activity.</p></sec><sec><title>Conclusion</title><p>This case highlights the need for careful MeHb monitoring and a multidisciplinary approach to manage ischemia safely in neonates undergoing GTN therapy.</p></sec></abstract><kwd-group><kwd>neonates</kwd><kwd>prematurity</kwd><kwd>methemoglobinemia</kwd><kwd>nigroglycerine</kwd><kwd>ischemia</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">IRCCS Istituto Giannina Gaslini</funding-source><award-id award-type="contract" rid="cn001">UAUT (2022_258_0)</award-id></award-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The APC was funded by an IRCCS Istituto Giannina Gaslini research grant [UAUT (2022_258_0)].</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="30"/><page-count count="6"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neonatology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="background" id="s1"><label>1</label><title>Background</title><p>The primary role of haemoglobin (Hb) in organisms is to facilitate oxygen transport. This function is ensured by the presence of a reduced form of heme iron (ferrous form, Fe2+) in the Hb structure (<xref rid="B1" ref-type="bibr">1</xref>). Methaemoglobin (MeHb) represents an altered structure of Hb caused by the oxidation of the heme iron into the dysfunctional ferric form (Fe3+), which cannot bind oxygen molecules. Inside red blood cells, a system known as the &#x0201c;MeHb reduction system&#x0201d; prevents this phenomenon through the nicotinamide adenine dinucleotide (NADH)-MeHb reductase pathway. This pathway involves a soluble cytochrome b5 and NADH-cytochrome b5 reductase (<xref rid="B2" ref-type="bibr">2</xref>). However, when the equilibrium between oxidation and reduction is disrupted by factors such as excessive oxidants, reduced reducing capacity (genetically determined or transient), or abnormal Hb forms, it can lead to methemoglobinemia, which sometimes represents a lifelong concern (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>Among the oxidants, nitric oxide (NO), an endogenous mediator of essential processes, such as vasodilation and transmission of nerve impulses, plays an important role. NO has a short half-life of approximately 4&#x02005;s and acts by activating the guanylate cyclase enzyme, thus increasing cyclic guanosine monophosphate (cGMP) levels, which causes vasodilatation and improves circulation (<xref rid="B4" ref-type="bibr">4</xref>). The process includes binding to the heme group of Hb, resulting in the formation of MeHb, followed by the elimination of nitrites and nitrates, primarily through renal excretion (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Many topical vasodilators, such as glyceryl trinitrate (GTN) patches, are based on NO to reduce local smooth muscle tone (<xref rid="B6" ref-type="bibr">6</xref>). Once absorbed by the skin barrier, this substance can gradually release NO in a relatively safe amount, even if the reaction proceeds in a sigmoidal fashion, which makes it relatively easy to reach toxic levels (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Severe limb ischemia after arterial catheterization is a known concern in premature infants. Arterial lines are often inserted for blood gas analysis, blood tests, and continuous monitoring of systemic blood pressure, particularly during the first few days after birth. However, this practice can lead to ischemia and tissue necrosis in the extremities, primarily due to the narrow arterial diameter and immature vascular compensatory mechanisms, particularly in infants with very low birth weight (VLBW) and/or intrauterine growth restriction (IUGR) (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>Topical applications of vasoactive patches have proven to be effective among therapies (<xref rid="B9" ref-type="bibr">9</xref>). However, in some cases, they have been linked to systemic complications, primarily due to elevated MeHb levels during treatment, which sometimes necessitate an increase in the administered oxygen fraction (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>).</p><p>Here, we report the case of an extremely preterm infant who underwent topical therapy with GTN for catheter-related limb ischemia and displayed a similar increase in the MeHb fraction.</p></sec><sec id="s2"><label>2</label><title>Case presentation</title><p>A female newborn was delivered at 25&#x02009;+&#x02009;4 weeks of gestational age with a birth weight of 560&#x02005;g (13th centile according to Bertino 2010 Italian growth charts) (<xref rid="B12" ref-type="bibr">12</xref>) by urgent cesarean section for maternal HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets). Pregnancy was achieved by medically assisted procreation and was characterized by severe IUGR with evidence of impaired umbilical and cerebral arterial velocimetry and severe preeclampsia under pharmacological therapy. APGAR scores 0, 6, 8 at 1st, 5th, and 10th minutes respectively. The patient was intubated in the delivery room and mechanically ventilated for the following two weeks of life, initially by conventional pressure-supported ventilation, followed by high-frequency oscillatory ventilation for severe hypercarbia. Due to lung immaturity and elevated FiO2 requirements (100% with SpO2 values persistently below the desired target, despite maximized ventilatory support), two exogenous surfactant administrations were necessary according to the European Consensus Guidelines on the Management of Respiratory Distress Syndrome (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>Within the first hour of life, an umbilical arterial line was positioned for arterial pressure monitoring. Owing to persistent hypotension, target pressure was achieved using incremental doses of dopamine, dobutamine, and adrenaline. Inotropic therapy was required for a week and then discontinued.</p><p>After 5&#x02005;h of life, the patient displayed impaired perfusion in the right hand's 1st, 2nd, and 3rd fingers (<xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>). GTN topical therapy was promptly initiated by applying a half patch on the site (the full patch is 9&#x02005;cm<sup>2</sup> containing 18.7&#x02005;mg of the drug) (<xref rid="B14" ref-type="bibr">14</xref>). After 16&#x02005;h of life, similar signs of ischemia were noticed in the homolateral foot, so an additional half of a GTN patch was applied.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Right-hand ischemia of the 1st, 2nd, and 3rd fingers before GTN patch application.</p></caption><graphic xlink:href="fped-13-1505233-g001" position="float"/></fig><p>During routine blood gas analyses, a severe consensual peak of 5.9% (determined at 18&#x02005;h of life) in the MeHb% fraction was recorded, so both patches were promptly removed. After another 18&#x02005;h, a new determination confirmed the normalization of MeHb% levels; a new application of a &#x000bc; patch was performed at both ischemic sites.</p><p>Therapy was continued at the same dosage for the following 118&#x02005;h and then discontinuation was attempted with success and total recovery of tissue perfusion.</p><p>We were able to rule out the existence of congenital methemoglobinemia since MeHb% levels became normal after GTN therapy discontinuation.</p><p><xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref> reports the entire MeHb% monitoring in detail. It shows a slight oscillatory trend after the application of the additional GTN patch in the right foot (within the safety ranges) and a second minor peak at 8&#x02005;h after reduction of dose to &#x000bc; patch.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Trend of the meHb% levels according to the hours of life. The black arrows indicate the application of the GTN patches. Short lines represent the use of half a patch, while long lines represent the application of half a patch at two different sites (totaling one full patch). The upward arrows mark the start of therapy, and the downward arrows indicate when therapy is discontinued. The last three short arrows correspond to the application of a quarter patch at two different sites (totaling half a patch).</p></caption><graphic xlink:href="fped-13-1505233-g002" position="float"/></fig></sec><sec sec-type="discussion" id="s3"><label>3</label><title>Discussion</title><p>Peripheral ischemia in neonates, particularly in extremely preterm and IUGR infants, is a challenging condition that requires careful management. In these cases, therapies such as GTN, a vasodilator, are commonly employed to improve blood flow, especially when standard conservative treatments fail (<xref rid="B9" ref-type="bibr">9</xref>). However, as this case report highlights, GTN therapy can sometimes lead to complications, including a rise in MeHb levels, which may impact oxygenation (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>MeHb levels are routinely measured via spectrophotometry through point-of-care blood gas analyzers (<xref rid="B15" ref-type="bibr">15</xref>), with a reported safety range of less than 1.5% (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). In our case, we observed increased MeHb% levels during topical GTN therapy for arterial catheter-related ischemia. Although this phenomenon has been reported in similar cases, there is limited evidence regarding the exact safety guidelines for using GTN in neonates. The frequency, duration, and safety of GTN use are poorly defined, and this treatment approach remains somewhat controversial (<xref rid="B18" ref-type="bibr">18</xref>). A literature review conducted by us identifies only two comparable case reports documenting an elevation in MeHb% levels following topical treatment for catheter-related hypoperfusion in preterm infants (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>) (<xref rid="T1" ref-type="table">Table 1</xref>). We acknowledge another case report, published by Ya Seul Han et al. in 2024, dealing with a highly preterm baby who developed severe tissue ischemia after arterial catheterization of the radial artery and was successfully treated using extensive humidification and topical nitroglycerin ointment application until complete clinical recovery; this article was excluded from our review since it is written in Chinese (<xref rid="B19" ref-type="bibr">19</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Review of the existing reports.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Article</th><th valign="top" align="center" rowspan="1" colspan="1">Patients</th><th valign="top" align="center" rowspan="1" colspan="1">GA/BW</th><th valign="top" align="center" rowspan="1" colspan="1">Application sites</th><th valign="top" align="center" rowspan="1" colspan="1">GTN dose</th><th valign="top" align="center" rowspan="1" colspan="1">Arterial catheters</th><th valign="top" align="center" rowspan="1" colspan="1">MeHb% max</th><th valign="top" align="center" rowspan="1" colspan="1">Duration of therapy</th><th valign="top" align="center" rowspan="1" colspan="1">Perfusion outcome</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="2" colspan="1">Mintoft et al., 2018 (<xref rid="B11" ref-type="bibr">11</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Case #1</td><td valign="top" align="left" rowspan="1" colspan="1">24 wks/650&#x02005;g</td><td valign="top" align="left" rowspan="1" colspan="1">Foot bilateral (2 patches), hand unilateral (1 patch)</td><td valign="top" align="center" rowspan="1" colspan="1">56.1&#x02005;mg</td><td valign="top" align="center" rowspan="1" colspan="1">RAL</td><td valign="top" align="center" rowspan="1" colspan="1">8.4</td><td valign="top" align="center" rowspan="1" colspan="1">2 days</td><td valign="top" align="left" rowspan="1" colspan="1">Recovery</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Case #2</td><td valign="top" align="left" rowspan="1" colspan="1">24 wks/617&#x02005;g</td><td valign="top" align="left" rowspan="1" colspan="1">Foot unilateral (2 patches)</td><td valign="top" align="center" rowspan="1" colspan="1">37.4&#x02005;mg</td><td valign="top" align="center" rowspan="1" colspan="1">TAL</td><td valign="top" align="center" rowspan="1" colspan="1">23.3</td><td valign="top" align="center" rowspan="1" colspan="1">5 days</td><td valign="top" align="left" rowspan="1" colspan="1">Finger necrosis (no amputation required)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pereira at al., 2022 (<xref rid="B10" ref-type="bibr">10</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">Case #3</td><td valign="top" align="left" rowspan="1" colspan="1">26 wks/580&#x02005;g (IUGR)</td><td valign="top" align="left" rowspan="1" colspan="1">Foot unilateral (1.5 patches<xref rid="table-fn2" ref-type="table-fn"><sup>a</sup></xref>)</td><td valign="top" align="center" rowspan="1" colspan="1">28.05&#x02005;mg</td><td valign="top" align="center" rowspan="1" colspan="1">UAL</td><td valign="top" align="center" rowspan="1" colspan="1">44.1</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 days</td><td valign="top" align="left" rowspan="1" colspan="1">Recovery</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>GA, gestational age; BW, birth weight; GTN, glyceryl trinitrate; MeHb%, percentual fraction of methaemoglobin; RAL, radial artery line; TAL, tibial artery line; UAL, umbilical artery line.</p></fn><fn id="table-fn2"><label>
<sup>a</sup>
</label><p>Erroneous application of 3 full patches for a period of 5&#x02005;h.</p></fn></table-wrap-foot></table-wrap><p>In these cases, the increase in MeHb% levels resulted in a significant and persistent decrease in oxygen saturation, which required increased the fraction of inspired oxygen (FiO2) during mechanical ventilation. However, in our case, it was difficult to establish a direct causal link between elevated MeHb% and increased FiO2, as our patient was extremely preterm and IUGR with unstable respiratory status due to respiratory distress syndrome (RDS) and suspected pulmonary hypoplasia. This differs from the other cases where oxygen requirements were stable before the rise in MeHb% levels, suggesting that their respiratory condition remained more stable and that fluctuations in oxygen needs were likely related to the increase in MeHb%. Therefore, we recommend that FiO2% should not be used as a reliable marker of MeHb intoxication, particularly in critically ill patients.</p><p>The reported cases also highlighted a range of MeHb% levels, with peaks between 8.4% and 44.1%. This suggests that even modest increases in MeHb% can impair oxygen exchange, making it critical to monitor infants closely during topical vasodilatory therapy. This is particularly true for extremely preterm and IUGR infants, whose skin is more permeable compared to term-born infants, potentially leading to greater absorption of the drug and an increased risk of adverse effects (<xref rid="B20" ref-type="bibr">20</xref>). Additionally, premature infants have lower levels of NADH-MeHb reductase and NADH-cytochrome b5 reductase (<xref rid="B21" ref-type="bibr">21</xref>), making them more susceptible to MeHb toxicity. These compensatory mechanisms are reliant on NADH levels, and critically ill infants may face heightened vulnerability due to systemic inflammatory insults compared to those in a more stable postnatal period.</p><p>Further complicating the issue is the fact that preterm infants have higher levels of fetal hemoglobin (FHb), which is more easily converted to MeHb than adult hemoglobin (<xref rid="B22" ref-type="bibr">22</xref>). This, combined with oxidative stress and reduced co-enzyme levels, makes them more susceptible to MeHb intoxication, as reported in studies on retinopathy of prematurity (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>).</p><p>While GTN therapy is effective in treating peripheral ischemia in neonates, when other treatments fail (<xref rid="B25" ref-type="bibr">25</xref>), its use must be approached cautiously. Several alternative therapies may also offer potential benefits. For example, vasodilatory treatments such as eNOS (endothelial nitric oxide synthase) modulators and prostacyclin analogs could improve peripheral circulation but require careful administration to avoid systemic hypotension (<xref rid="B26" ref-type="bibr">26</xref>). Another potential treatment is nimodipine, a calcium channel blocker that effectively reduces vasoconstriction and improves blood flow in neonates with cerebral vasospasm. This drug could also benefit neonates with peripheral ischemia, though further research is needed (<xref rid="B27" ref-type="bibr">27</xref>). Emerging therapies, such as stem cell treatments, are also being explored. For instance, human-induced pluripotent stem-cell-derived smooth muscle cells have shown promise in increasing angiogenesis in animal models. Still, their safety and feasibility in neonates, especially in preterm infants, remain uncertain (<xref rid="B28" ref-type="bibr">28</xref>).</p><p>Surgical interventions like vascular reconstruction or endovascular procedures may sometimes be considered. However, these are typically reserved for more severe cases due to the high risks and technical complexity associated with preterm infants (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>While several therapeutic options exist for managing peripheral ischemia in neonates, particularly in preterm and IUGR infants, each option comes with its own set of challenges and risks. The management approach must be individualized, taking into account the fragile cardiovascular system, limited capacity for tissue regeneration, and heightened risk of complications in these vulnerable infants. A systematic review has suggested that topical nitroglycerine ointment may offer a favorable balance between effectiveness and safety for treating ischemia in newborns compared to other forms of GTN administration, such as patches or sprays (<xref rid="B30" ref-type="bibr">30</xref>). Nonetheless, more robust evidence and clearer guidelines are needed to optimize the use of vasodilators like GTN in this patient population.</p></sec><sec sec-type="conclusions" id="s4"><label>4</label><title>Conclusion</title><p>This is the fourth case of increased MeHb during topical vasodilatory therapy for extremity ischemia in an extremely premature baby. The data indicate that an elevated percentage of MeHb is often linked to significant complications, particularly those affecting respiratory and oxidative functions, which can result in severe outcomes in this vulnerable patient population.</p><p>Therefore, managing peripheral ischemia in neonates with GTN should involve a multidisciplinary approach that includes close monitoring of blood pressure and MeHb levels, along with comprehensive follow-up examinations.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to the IRCCS Istituto Giannina Gaslini for the support in the several steps leading to the approval and publishing the study.</p></ack><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="ab001"><p>Hb, hemoglobin; MeHb, methemoglobin; NAD(H), nicotinamide adenine dinucleotide; NO, nitric oxide; cGMP, cyclic guanosine monophosphate; GTN, glyceryl trinitrate; VLBW, very low birth weight; IUGR, Intrauterine growth restriction; HELLP, hemolysis, elevated liver enzymes, and low platelets; FiO2, oxygen inhaled fraction; SpO2, peripheral oxygen saturation of Hb; RDS, respiratory distress syndrome.</p></fn></fn-group><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>Ethical approval was not required for the study involving human samples in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participant(s) and the participants' legal guardians/next of kin. Written informed consent was obtained from the individual(s) and the minor(s)' legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>AC: Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing, Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration. FV: Conceptualization, Investigation, Methodology, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. MB: Conceptualization, Data curation, Writing &#x02013; original draft. SC: Conceptualization, Investigation, Methodology, Writing &#x02013; original draft. CA: Methodology, Validation, Writing &#x02013; review &#x00026; editing. CM: Data curation, Methodology, Writing &#x02013; original draft. MV: Conceptualization, Supervision, Validation, Writing &#x02013; review &#x00026; editing. DM: Methodology, Supervision, Validation, Writing &#x02013; review &#x00026; editing. GB: Funding acquisition, Project administration, Resources, Writing &#x02013; review &#x00026; editing. LR: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The authors declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>A</given-names></name></person-group>. <article-title>Methemoglobinemia</article-title>. <source>Am J Med Sci</source>. (<year>1985</year>) <volume>289</volume>(<issue>5</issue>):<fpage>200</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00000441-198505000-00004</pub-id><pub-id pub-id-type="pmid">4003427</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>L</given-names></name><name><surname>Spyker</surname><given-names>DA</given-names></name></person-group>. <article-title>NADH-methemoglobin reductase activity: adult versus child</article-title>. <source>Clin Toxicol</source>. (<year>2018</year>) <volume>56</volume>(<issue>9</issue>):<fpage>866</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1080/15563650.2018.1444768</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaff&#x000e9;</surname><given-names>ER</given-names></name></person-group>. <article-title>Methemoglobin pathophysiology</article-title>. <source>Prog Clin Biol Res</source>. (<year>1981</year>) <volume>51</volume>:<fpage>133</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">7022466</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignarro</surname><given-names>LJ</given-names></name><name><surname>Cirino</surname><given-names>G</given-names></name><name><surname>Casini</surname><given-names>A</given-names></name><name><surname>Napoli</surname><given-names>C</given-names></name></person-group>. <article-title>Nitric oxide as a signaling molecule in the vascular system: an overview</article-title>. <source>J Cardiovasc Pharmacol</source>. (<year>1999</year>) <volume>34</volume>(<issue>6</issue>):<fpage>879</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1097/00005344-199912000-00016</pub-id><pub-id pub-id-type="pmid">10598133</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DG</given-names></name><name><surname>Litchfield</surname><given-names>MH</given-names></name></person-group>. <article-title>Role of inorganic nitrite in methaemoglobin formation after nitrate ester administration to the rat</article-title>. <source>Br J Pharmacol</source>. (<year>1973</year>) <volume>48</volume>(<issue>1</issue>):<fpage>162</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1973.tb08235.x</pub-id><pub-id pub-id-type="pmid">4198921</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalupsk&#x000fd;</surname><given-names>K</given-names></name><name><surname>Bart&#x000ed;k</surname><given-names>P</given-names></name><name><surname>Eklov&#x000e1;</surname><given-names>S</given-names></name><name><surname>Entlicher</surname><given-names>G</given-names></name></person-group>. <article-title>Possible metabolic pathways of conversion of formaldoxime and glyceryl trinitrate to NO</article-title>. <source>Gen Physiol Biophys</source>. (<year>2003</year>) <volume>22</volume>(<issue>2</issue>):<fpage>233</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">14661735</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarburton</surname><given-names>JP</given-names></name><name><surname>Metcalf</surname><given-names>WK</given-names></name></person-group>. <article-title>Kinetics of amyl nitrite-induced hemoglobin oxidation in cord and adult blood</article-title>. <source>Toxicology</source>. (<year>1985</year>) <volume>36</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/0300-483X(85)90003-4</pub-id><pub-id pub-id-type="pmid">2862720</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deindl</surname><given-names>P</given-names></name><name><surname>Waldh&#x000f6;r</surname><given-names>T</given-names></name><name><surname>Unterasinger</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Keck</surname><given-names>M</given-names></name></person-group>. <article-title>Arterial catheterisation in neonates can result in severe ischaemic complications but does not impair long-term extremity function</article-title>. <source>Acta Paediatr</source>. (<year>2018</year>) <volume>107</volume>(<issue>2</issue>):<fpage>240</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/apa.14100</pub-id><pub-id pub-id-type="pmid">28960442</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyce</surname><given-names>L</given-names></name><name><surname>Dhukaram</surname><given-names>V</given-names></name></person-group>. <article-title>Transdermal glyceryl trinitrate in the treatment of ischemia following toe deformity correction: a case series</article-title>. <source>Foot Ankle Int</source>. (<year>2014</year>) <volume>35</volume>(<issue>11</issue>):<fpage>1226</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1177/1071100714546887</pub-id><pub-id pub-id-type="pmid">25125514</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>SS</given-names></name><name><surname>Yeldo</surname><given-names>B</given-names></name><name><surname>Aladangady</surname><given-names>N</given-names></name></person-group>. <article-title>Methaemoglobinaemia associated with use of glyceryl trinitrate patches in an extremely preterm infant</article-title>. <source>J Paediatr Child Health</source>. (<year>2022</year>) <volume>58</volume>(<issue>10</issue>):<fpage>1862</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1111/jpc.15996</pub-id><pub-id pub-id-type="pmid">35474378</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mintoft</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>C</given-names></name><name><surname>Kennea</surname><given-names>N</given-names></name><name><surname>Greenough</surname><given-names>A</given-names></name></person-group>. <article-title>Methemoglobinemia during the use of glyceryl trinitrate patches in neonates: two case reports</article-title>. <source>AJP Rep</source>. (<year>2018</year>) <volume>8</volume>(<issue>4</issue>):<fpage>e227</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1055/s-0038-1669945</pub-id><pub-id pub-id-type="pmid">30345159</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertino</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Neonatal anthropometric charts: the Italian neonatal study compared with other European studies</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. (<year>2010</year>) <volume>51</volume>(<issue>3</issue>):<fpage>353</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1097/MPG.0b013e3181da213e</pub-id><pub-id pub-id-type="pmid">20601901</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweet</surname><given-names>DG</given-names></name><etal/></person-group>
<article-title>European consensus guidelines on the management of respiratory distress syndrome: 2022 update</article-title>. <source>Neonatology</source>. (<year>2023</year>) <volume>120</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1159/000528914</pub-id><pub-id pub-id-type="pmid">36863329</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varughese</surname><given-names>M</given-names></name><name><surname>Koh</surname><given-names>THHG</given-names></name></person-group>. <article-title>Successful use of topical nitroglycerine in ischaemia associated with umbilical arterial line in a neonate</article-title>. <source>J Perinatol</source>. (<year>2001</year>) <volume>21</volume>(<issue>8</issue>):<fpage>556</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jp.7210567</pub-id><pub-id pub-id-type="pmid">11774020</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calandrino</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Optimizing haemoglobin measurements in VLBW newborns: insights from a comparative retrospective study</article-title>. <source>Early Hum Dev</source>. (<year>2024</year>) <volume>190</volume>. <pub-id pub-id-type="doi">10.1016/j.earlhumdev.2024.105949</pub-id><pub-id pub-id-type="pmid">38290276</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kravitz</surname><given-names>H</given-names></name><name><surname>Elegant</surname><given-names>LD</given-names></name><name><surname>Kaiser</surname><given-names>E</given-names></name><name><surname>Kagan</surname><given-names>BM</given-names></name></person-group>. <article-title>Methemoglobin values in premature and mature infants and children</article-title>. <source>AMA J Dis Child</source>. (<year>1956</year>) <volume>91</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1956.02060020003001</pub-id><pub-id pub-id-type="pmid">13275111</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haymond</surname><given-names>S</given-names></name><name><surname>Cariappa</surname><given-names>R</given-names></name><name><surname>Eby</surname><given-names>CS</given-names></name><name><surname>Scott</surname><given-names>MG</given-names></name></person-group>. <article-title>Laboratory assessment of oxygenation in methemoglobinemia</article-title>. <source>Clin Chem</source>. (<year>2005</year>) <volume>51</volume>(<issue>2</issue>):<fpage>434</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2004.035154</pub-id><pub-id pub-id-type="pmid">15514101</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosalli</surname><given-names>R</given-names></name><name><surname>Khayyat</surname><given-names>W</given-names></name><name><surname>Al Qarni</surname><given-names>S</given-names></name><name><surname>Al Matrafi</surname><given-names>A</given-names></name><name><surname>El Baz</surname><given-names>M</given-names></name><name><surname>Paes</surname><given-names>B</given-names></name></person-group>. <article-title>Topical nitroglycerin in newborns with ischemic injuries: a systematic review</article-title>. <source>Saudi Pharm J</source>. (<year>2021</year>) <volume>29</volume>(<issue>7</issue>):<fpage>764</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsps.2021.05.008</pub-id><pub-id pub-id-type="pmid">34400871</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>YS</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Sung</surname><given-names>TJ</given-names></name><name><surname>Chun</surname><given-names>J</given-names></name></person-group>. <article-title>Successful management of severe peripheral tissue ischemia after arterial catheterization in micro preemies using humidification &#x00026; topical nitroglycerin</article-title>. <source>Neonatal Med</source>. (<year>2017</year>) <volume>24</volume>(<issue>4</issue>):<fpage>197</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.5385/nm.2017.24.4.197</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinsker</surname><given-names>JE</given-names></name><name><surname>McBayne</surname><given-names>K</given-names></name><name><surname>Edwards</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Crudo</surname><given-names>DF</given-names></name><name><surname>Bauer</surname><given-names>AJ</given-names></name></person-group>. <article-title>Transient hypothyroidism in premature infants after short-term topical iodine exposure: an avoidable risk?</article-title>
<source>Pediatr Neonatol</source>. (<year>2013</year>) <volume>54</volume>(<issue>2</issue>):<fpage>128</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.pedneo.2012.10.005</pub-id><pub-id pub-id-type="pmid">23590958</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamon</surname><given-names>I</given-names></name><name><surname>Gauthier-Moulinier</surname><given-names>H</given-names></name><name><surname>Grelet-Dessioux</surname><given-names>E</given-names></name><name><surname>Storme</surname><given-names>L</given-names></name><name><surname>Fresson</surname><given-names>J</given-names></name><name><surname>Hascoet</surname><given-names>JM</given-names></name></person-group>. <article-title>Methaemoglobinaemia risk factors with inhaled nitric oxide therapy in newborn infants</article-title>. <source>Acta Paediatr</source>. (<year>2010</year>) <volume>99</volume>(<issue>10</issue>):<fpage>1467</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.2010.01854.x</pub-id><pub-id pub-id-type="pmid">20456277</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fossen Johnson</surname><given-names>S</given-names></name></person-group>. <article-title>Methemoglobinemia: infants at risk</article-title>. <source>Curr Probl Pediatr Adolesc Health Care</source>. (<year>2019</year>) <volume>49</volume>(<issue>3</issue>):<fpage>57</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/J.CPPEDS.2019.03.002</pub-id><pub-id pub-id-type="pmid">30956100</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>G-S</given-names></name><name><surname>Dusting</surname><given-names>G</given-names></name></person-group>. <article-title>Redox mechanisms in pathological angiogenesis in the retina: roles for NADPH oxidase</article-title>. <source>Curr Pharm Des</source>. (<year>2015</year>) <volume>21</volume>(<issue>41</issue>):<fpage>5988</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.2174/1381612821666151029111127</pub-id><pub-id pub-id-type="pmid">26510439</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elizabeth Hartnett</surname><given-names>M</given-names></name></person-group>. <article-title>The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model</article-title>. <source>Doc Ophthalmol</source>. (<year>2010</year>) <volume>120</volume>(<issue>1</issue>):<fpage>25</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/s10633-009-9181-x</pub-id><pub-id pub-id-type="pmid">19639355</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasquez</surname><given-names>P</given-names></name><name><surname>Burd</surname><given-names>A</given-names></name><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>Hiatt</surname><given-names>M</given-names></name><name><surname>Hegyi</surname><given-names>T</given-names></name></person-group>. <article-title>Resolution of peripheral artery catheter-induced ischemic injury following prolonged treatment with topical nitroglycerin ointment in a newborn: a case report</article-title>. <source>J Perinatol</source>. (<year>2003</year>) <volume>23</volume>(<issue>4</issue>):<fpage>348</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/sj.jp.7210870</pub-id><pub-id pub-id-type="pmid">12774147</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name><name><surname>Steinhorn</surname><given-names>RH</given-names></name></person-group>. <article-title>Targeted therapies for neonatal pulmonary hypertension: beyond nitric oxide</article-title>. <source>Clin Perinatol</source>. (<year>2024</year>) <volume>51</volume>(<issue>1</issue>):<fpage>113</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.clp.2023.11.008</pub-id><pub-id pub-id-type="pmid">38325937</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGowan</surname><given-names>B</given-names></name><name><surname>Khaira</surname><given-names>G</given-names></name><name><surname>Coghlan</surname><given-names>MA</given-names></name><name><surname>Shaibani</surname><given-names>A</given-names></name><name><surname>Alden</surname><given-names>TD</given-names></name><name><surname>Pardo</surname><given-names>AC</given-names></name></person-group>. <article-title>Use of nimodipine in a neonate with cerebral vasospasm with delayed ischemia from subarachnoid hemorrhage in the posterior Fossa</article-title>. <source>Pediatr Neurol</source>. (<year>2020</year>) <volume>111</volume>:<fpage>44</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2020.06.018</pub-id><pub-id pub-id-type="pmid">32951659</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Human-induced pluripotent stem-cell-derived smooth muscle cells increase angiogenesis to treat hindlimb ischemia</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>(<issue>4</issue>). <pub-id pub-id-type="doi">10.3390/CELLS10040792</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arshad</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>MJ</given-names></name></person-group>. <article-title>Management of limb ischaemia in the neonate and infant</article-title>. <source>Eur J Vasc Endovasc Surg</source>. (<year>2009</year>) <volume>38</volume>(<issue>1</issue>):<fpage>61</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejvs.2009.03.010</pub-id><pub-id pub-id-type="pmid">19362027</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sushko</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Topical nitroglycerin ointment as salvage therapy for peripheral tissue ischemia in newborns: a systematic review</article-title>. <source>CMAJ Open</source>. (<year>2021</year>) <volume>9</volume>(<issue>1</issue>):<fpage>E252</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.9778/cmajo.20200129</pub-id><pub-id pub-id-type="pmid">33731426</pub-id>
</mixed-citation></ref></ref-list></back></article>